All In Biotech

NDA 019268 · Pfizer

Cytotec

Misoprostol · Oral · Prostaglandin E1 Analog

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Feb 28, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1988

Dec 27, 1988

Approved uses

1

Original approval plus efficacy supplements

Registered trials

481

104 Phase 3, 18 recruiting

FAERS reports

9,774

6,754 serious, 746 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNINGS MISOPROSTOL ADMINISTRATION TO WOMEN WHO ARE PREGNANT CAN CAUSE BIRTH DEFECTS, ABORTION, PREMATURE BIRTH OR UTERINE RUPTURE. UTERINE RUPTURE HAS BEEN REPORTED WHEN MISOPROSTOL WAS ADMINISTERED IN PREGNANT WOMEN TO INDUCE LABOR OR TO INDUCE ABORTION. THE RISK OF UTERINE RUPTURE INCREASES WITH ADVANCING GESTATIONAL AGES AND WITH PRIOR UTERINE SURGERY, INCLUDING CESAREAN DELIVERY (see also PRECAUTIONS and LABOR AND DELIVERY ). MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). PATIENTS MUST BE ADVISED OF THE ABORTIFACIENT PROPERTY AND WARNED NOT TO GIVE THE DRUG TO OTHERS. Misoprostol should not be used for reducing the risk of NSAID-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from...

What it is approved for

From the label in effect Nov 4, 2026.

INDICATIONS AND USAGE Misoprostol is indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Misoprostol should be taken for the duration of NSAID therapy. Misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • CYTOTEC · MISOPROSTOL 0.1MG · TABLET, ORAL · Prescription · TE AB
  • CYTOTEC · MISOPROSTOL 0.2MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Misoprostol" as an intervention, any sponsor and status, largest first.

All 481 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • haemorrhage1,260
  • abortion incomplete1,159
  • off label use924
  • foetal exposure during pregnancy652
  • pain542
  • anaemia511
  • pregnancy449
  • nausea448
  • drug ineffective442
  • vomiting427
  • maternal exposure during pregnancy420
  • pyrexia408

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004503
2005419
2006388
2007347
2008346
2009385
2010553
2011611
2012621
2013409
2014402
2015376
2016403
2017415
2018372
2019451
2020719
2021498
2022402
2023329
2024289
2025307
2026227

Recalls

1 FDA enforcement reports for this application.

  • Sep 9, 2016 · Class III · Terminated

    Failed Impurities/Degradations Specifications; Out of specification results for two known degradation products and total impurities at 18 months

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cytotec (Misoprostol)

2024 spending

$27K

Beneficiaries

n/a

20 claims

Per beneficiary

n/a

$5.44 per unit

View as table
YearSpending
2020$35,953
2021$50,486
2022$41,251
2023$33,330
2024$26,860

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,927 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.